Frederick Locke, MD

Articles

The Emerging Role of Second-line CAR T-cell Therapy in Relapsed/Refractory DLBCL

January 27th 2025

An analysis of key updates on CAR T-cell therapy in DLBCL from ZUMA-7 and TRANSFORM trials, exploring its potential as a primary second-line option, along with insights into efficacy and safety data for transplant-ineligible patients from ALYCANTE and PILOT studies

Second-line Treatment Landscape in Relapsed/Refractory DLBCL

January 27th 2025

A concise discussion of second-line treatment options for DLBCL, focusing on preferred regimens for transplant-eligible and ineligible patients, and tailored approaches based on relapse timing.

Role of Testing in Treatment Decisions - ClonoSeq, PhaseSeq, MRD+Disease

January 20th 2025

A concise discussion of second-line treatment strategies for DLBCL, highlighting preferred regimens for transplant-eligible and ineligible patients, as well as treatment approaches based on the timing of relapse.

Future Considerations for Front-line Treatment of DLBCL

January 20th 2025

An overview of key studies and updates from ASH 2024 offering new insights into subsequent treatment strategies and safety management in the first-line setting for DLBCL.

The Evolving First-line Treatment Approach for DLBCL

January 15th 2025

An exploration of how first-line treatment practices for DLBCL have evolved with new options, emphasizing the role of relapsed/refractory disease risk in guiding treatment selection.

Insights from POLARIX: How do Novel Perspectives Influence Treatment Outcomes in DLBCL?

January 15th 2025

An expert discussion on evolving first-line treatment strategies for newly diagnosed diffuse large B-cell lymphoma (DLBCL), incorporating insights from the 2024 NCCN guidelines, unmet needs in 1L therapies, and the impact of POLARIX trial updates on the use of Pola+R-CHP in clinical practice.

Emerging Updates in Front-line Treatment Approach of DLBCL

January 3rd 2025

Matthew Matasar, MD and Nilajan Ghosh, MD, PhD, discuss first-line treatment strategies for DLBCL, including factors influencing treatment selection, unmet needs in first-line treatment options, the impact of the 2024 NCCN guideline updates, and practical guidance for community practitioners following insights from the POLARIX trial.

Future Perspectives in Large B-Cell Lymphoma

December 26th 2023

Fred Locke, MD shares his perspective on the future treatment paradigm in large B-cell lymphoma, emphasizing CAR-T cells, allogeneic strategies, bispecifics, toxicity management, and treatment sequencing.

Emerging Bispecifics in the Treatment Paradigm for R/R LBCL

December 26th 2023

Expert discusses the emergence of recently approved bispecific antibodies in R/R LBCL, emphasizing the importance of toxicity management for adverse events such as cytokine release syndrome (CRS).

Observations in Progression Post-CAR T for Lymphoma

December 19th 2023

A comprehensive overview of clinical and patient factors that impact disease progression beyond CAR T-cell therapy in lymphoma.

Lisocabtagene Maraleucel: A Review of TRANSCEND NHL 001 in R/R LBCL

December 19th 2023

Gain insights into treatment outcomes of CAR T, highlighting lisocabtagene maraleucel and the TRANSCEND NHL 001 study for R/R LBCL.

ZUMA-1: Axi-Cel in Relapsed/Refractory LBCL

December 12th 2023

A dive into the latest results from the ZUMA-1 study, evaluating axicabtagene ciloleucel (axi-cel) in relapsed/refractory LBCL.

Approaches to Treatment Sequencing in LBCL

December 12th 2023

Expert perspective on treatment sequencing strategies for patients with LBCL.

CAR T: A Review of Clinical Data for Second Line Treatments of Large B-Cell Lymphoma

December 5th 2023

Dr. Locke reviews the latest data from ZUMA-7 and TRANSFORM studies, evaluating CAR T in the second line setting for R/R LBCL.

Exploring LBCL: Transplant Eligibility and Second Line Treatment Selection of Novel Agents

December 5th 2023

Fred Locke, MD, provides an overview of transplant eligibility for patients with large B-cell lymphoma, highlighting second line strategies with CAR T-cell therapy and bispecific antibodies.

Role of Bispecifics and Future Promising Treatments in DLBCL

August 11th 2022

Shared excitement for bispecific antibodies and other promising novel therapies in the treatment of patients with DLBCL.

The Future of DLBCL Treatment

August 11th 2022

A look at exciting investigational agents and clinical trials for patients with relapsed/refractory diffuse large B-cell lymphoma.

Management and Work-up of Patients for Salvage Therapy

August 8th 2022

The panelists share their approach to the treatment and work-up of patients who require salvage therapy.

Strategies for Supportive Care and Monitoring in Patients Who Have Received CAR T-Cell Therapy

August 8th 2022

Experts in lymphoma take part in a discussion on supportive care for patients who receive CAR T-cell therapy.

A Closer Look at CAR T-Cell Therapy Clinical Trial Design

July 28th 2022

Subject matter experts in lymphoma reflect on chimeric antigen receptor T-cell therapy clinical trial design.